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Background: Diabetes is characterized by chronic hyperglycemia and disturbances of carbohydrate, lipid and
protein metabolism. We aimed to research association between serum lipid profile and blood glucose,
hypothesizing that early detection and treatment of lipid abnormalities can minimize the risk for atherogenic
cardiovascular disorder and cerebrovascular accident in patients with type 2 diabetes mellitus.
Methods: Fasting blood glucose (FBG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein
(LDL), triglyceride (TG) and glycated haemoglobin (HbA1c) levels were evaluated. A hepatic ultrasound was
performed for every diabetic to evaluate hepatosteatosis. The study was done from January 2014 to June 2014
among 132 patients with T2DM who were admitted to outpatient clinic of Family Medicine department in a
university hospital. The patients whose taking multi-vitamin supplementation or having hepatic, renal or metabolic
bone disorders (including parathyroid related problems) were excluded from the study for the reason that those
conditions might affect the carbohydrate and lipid metabolism in diabetes. Test of significance was calculated by
unpaired student’s t test between cases and controls. Correlation studies (Pearson’s correlation) were performed
between the variables of blood glucose and serum lipid profile. Significance was set at p<0.05.
Results: Results of serum lipid profile showed that the mean values for TC, TG, HDL and LDL in female patients
were 227.6 ± 57.7 mg/dl, 221.6 ± 101.1 mg/dl, 31.5 ± 6.7 mg/dl and 136.5 ± 43.7 mg/dl, respectively. The mean
values for TC, TG, HDL and LDL in male patients were 219.1 ± 34.7 mg/dl, 250.0 ± 100.7 mg/dl, 30.2 ± 7.4 mg/dl
and 125.7 ± 21.4 mg/dl, respectively. Significantly higher mean serum levels of TC, TG and LDL and significantly
lower mean serum levels of HDL were noted in patients with diabetes (p<0.001). FBG showed significant positive
correlation with TC (p<0.05) and TG (p<0.05). Significant correlations were observed between serum levels of TC,
TG, LDL and hepatosteatosis and HbA1c (p<0.05).
Conclusions: The study showed widespread lipid abnormalities in the course of diabetes triggered dyslipidemia as
hypercholesterolemia, hypertriglyceridemia, elevated LDL and decreased HDL. This study proposes the
predominance of hyperlipidemia over increased prevalence of diabetic dyslipidemia.
Keywords: Dyslipidemia, Glucose intolerance, Insulin resistance, Type 2 diabetes, Lifestyle modificationBackground
Diabetes mellitus is a common metabolic disorder char-
acterized by absolute or relative deficiencies in insulin
secretion and/or insulin action associated with chronic
hyperglycemia and disturbances of carbohydrate, lipid
and protein metabolism [1]. Several previous studiesCorrespondence: aclan.ozder@aol.com
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unless otherwise stated.have attempted to correlate blood glucose levels with
serum lipid profile parameters [2,3]. Research findings
show that mainly body fat is responsible for increase in
prevalence of this disease among the body composition
components [1,4,5]. As early as 1988, it was described a
multifactorial metabolic abnormality consisting of insu-
lin resistance with compensatory hyperinsulinaemia,
type 2 diabetes mellitus (T2DM), essential hypertension
and hypercholesterolaemia [6,7]. Today, however, theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Gender distribution and age of patients with
type 2 diabetes
Gender No. of patients Age1
Female 81 55.5 ± 9.2
Male 51 54.8 ± 12.6
Total 132 55.3 ± 10.5
1Units expressed as years.
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Diabetes Federation (IDF) use the term “Metabolic
Syndrome” to describe this clustering of conditions [8].
The term diabetic dyslipidemia comprises a triad of raised
triglycerides, reduced high density lipoprotein (HDL) and
excess of small, dense low density lipoprotein (LDL) parti-
cles. The lipid abnormalities are prevalent in diabetes
mellitus because insulin resistance or deficiency affects
key enzymes and pathways in lipid metabolism [9]. Micro-
vascular and macro-vascular complications, including
cardiovascular disease (CVD), retinopathy, nephropathy,
and neuropathy, occur due to chronic uncontrolled hyper-
glycemia in diabetics [10,11]. It has been proposed that
the composition of lipid particles in diabetic dyslipidemia
is more atherogenic than other types of dyslipidemia [12].
The causal association between atherosclerosis and dyslip-
idemia is well established. In diabetes the associated
hyperglycemia, obesity and insulin changes highly acceler-
ate the progression to atherosclerosis [13,14]. In a recent
study, it was observed significant trends for rising risk of
coronary heart disease, stroke and all-cause mortality in
relation to higher levels of baseline HbA1c in more than
11,000 participants in the Atherosclerosis Risk in Commu-
nities Study. For HbA1c categories of <6.5% and ≥ 6.5%,
there was a significant association between fasting blood
glucose levels and coronary heart disease, stroke or death
from any cause [15]. It was attempted to correlate blood
glucose levels with serum lipid profile parameters in previ-
ous studies [2] and it is clear that HbA1c values are lower
in individuals with a decreased risk of micro-vascular
complications [15].
In the present study, we aimed to research association be-
tween serum lipid profile and blood glucose, hypothesizing
that early detection and treatment of lipid abnormalities
can minimize the risk for atherogenic cardiovascular
disorder and cerebrovascular accident in patients with
type 2 diabetes mellitus.Results
We evaluated clinical and laboratory findings in 132
patients with T2DM. Of the total number of subjects,
61.4% (81) were females, and 38.6% (51) of the subjects
were males (Table 1). The age range and mean age of
female subjects was 37–75 years and 55.5 ± 9.2 while the
age range and mean age for male subjects was 39–84
years and 54.8 ± 12.6 years, respectively. The mean BMI
of the participants was 28.59 ± 3.25 kg/m2 (range: 26.10-
44.98). Eleven out of 132 patients were obese in this
study with BMI ranging from 31.02 to 44.98.
Results of the blood glucose profile showed that all
individuals were hyperglycaemic. The fasting blood
glucose and HbA1c percentage among entire group was
shown in Table 2.Results of serum lipid profile showed that there is no
statistically significant difference between diabetic fe-
males and males as TC, TG, HDL and LDL compared
(p > 0.05). However, a significant difference was found as
compared to normal range for related serum lipids of
diabetics (p < 0.001) (Table 3).
Mean value of the TG/HDL ratio which is considered
a surrogate marker of insulin resistance was 7.98 ± 3.87
among entire group. In correlation studies, TG/HDL ra-
tio showed significant positive correlation with HbA1c
(p < 0.01). Among all patients, hypercholesterolemia was
found in 93 (70.5%) individuals. Similarly, increased LDL
cholesterol was found in 117 (88.6%) individuals. Of the
participants only 39 (29.5%) were found to have normal
values for TG. Grade I and II hepatosteatosis were found
in nearly one third of diabetics and Grade III hepatostea-
tosis in 63 (47.7%) subjects while Grade IV hepatosteato-
sis was found in 27 (20.5%) of the study group by
hepatic ultrasound (Table 4).
In correlation studies, FBG showed significant positive
correlation with cholesterol (p < 0.05) and TG (p < 0.05).
The correlation of cholesterol with TG (p < 0.001) and
LDL cholesterol (p < 0.001) were positive. However, HDL
cholesterol showed a negative correlation with LDL chol-
esterol (p < 0.01). Findings were presented in Table 5.
Discussion
There were more females (61.4%) than males (38.6%)
with T2DM in this study. The high proportion of fe-
males in this study may be due to the nature of popula-
tion admitting to this hospital in that more of them seek
medical attention than men under favour of having more
free time because most of them were housewives.
In patients with diabetes, many studies have clearly
established that complications are mainly due to chronic
hyperglycemia that exerts its injurious to health effects
through several mechanisms: dyslipidemia, platelet acti-
vation, and altered endothelial metabolism [16-18]. Both
lipid profile and diabetes have been shown to be the im-
portant predictors for metabolic disturbances including
dyslipidaemia, hypertension, cardiovascular diseases [19].
Lipids play a vital role in the pathogenesis of diabetes
mellitus. Dyslipidemia as a metabolic abnormality is fre-
quently associated with diabetes mellitus. Abnormalities
in lipid metabolism have been reported in patients with
Table 2 The concentration of fasting blood glucose and
HbA1c percentage in diabetic patients
Normal range Study group range Mean
Glucose (FBG)1
Female 70 – 100 109–337 196.7 ± 61.22
Male 70 – 100 135–339 217.1 ± 57.52
HbA1c3
Female <6.5 6.5-11.30 8.46 ± 1.494
Male <6.5 6.5-11.40 8.84 ± 1.534
1Units expressed as mg/dl.
2Statistically significant (p < 0.001) as compared to normal range for plasma
blood glucose.
3Units expressed as percentage (%).
4Statistically significant (p < 0.001) as compared to normal range for HbA1c.
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vascular arteriosclerosis [20]. In the present study, sig-
nificantly higher mean serum levels of total cholesterol,
triglycerides and LDL cholesterol were noted in patients
with diabetes, which are well known risk factors for
cardiovascular diseases among patients, when compared
to the normal values (Table 3).
In diabetes many factors may affect blood lipid levels,
because of interrelationship between carbohydrates and
lipid metabolism. Therefore, any disorder in carbo-
hydrate metabolism leads to disorder in lipid metabolism
and vice versa. Insulin resistance is a primary defect in
the majority of patients with T2DM. In non-diabetic
individuals insulin resistance in combination with
hyperinsulinemia has a strong predictive value for future
development for type 2 diabetes [21]. Several studies
showed that insulin affects the liver apolipoprotein pro-
duction and regulates the enzymatic activity of lipopro-
tein lipase and cholesterol ester transport protein, which
causes dyslipidemia in diabetes mellitus. Moreover, insu-
lin deficiency reduces the activity of hepatic lipase and
several steps in the production of biologically active lipo-
protein lipase [4,22,23]. Hypertriglyceridaemia usually
accompanies decreased HDL cholesterol, which is also a
prominent feature of plasma lipid abnormalities seen in
individuals with diabetes [24,25]. The cluster of lipid
abnormalities associated with T2DM is defined by a high
concentration of TG and small dense LDL and a lowTable 3 The results of TC, TG, HDL and LDL in serum of diabe
Lipid Female
Normal range Study group Mean
TC1 <200 137-396 227.6 ± 57.72
TG1 <150 89-411 221.6 ± 101.1
HDL1 45-65 24-50 31.5 ± 6.7
LDL1 <100 69-274 136.5 ± 43.72
1Units expressed as mg/dl.
2Statistically significant (p < 0.001) as compared to normal range for related serum lconcentration of HDL cholesterol. The association be-
tween reduced HDL cholesterol levels and increased risk
of heart disease is, on the other hand, well established,
independently of TG levels and other risk factors
[26,27]. The possible mechanism responsible for hyper-
triglyceridaemia may be due to increased hepatic secre-
tion of very low density lipoprotein (VLDL) and delayed
clearance of triglyceride rich lipoproteins, which is pre-
dominantly due to increased levels of substrates for tri-
glyceride production, free fatty acids and glucose [28]. In
the present study, significant correlations were observed
between serum levels of total cholesterol, triglycerides,
LDL cholesterol and hepatosteatosis and blood concen-
trations of HbA1c (Table 5). Results of the correlation
studies suggest a clear association between hypergly-
cemia and appearance of dyslipidemia. Our findings
were in line with a previous study suggesting that the
level of total cholesterol is usually normal or near nor-
mal if glycaemic control is adequate, and worsening of
control raises the level [29]. Therefore, improving gly-
caemic control might substantially reduce the risk of
cardiovascular events in diabetic patients.
Abnormal glucose reading is the commonest meta-
bolic abnormality in people with T2DM accompanied by
lower HDL levels, elevated LDL, hypercholesterolaemia,
and hypertriglyceridaemia. Poor glycaemic control and
hypertriglyceridaemia are significant biochemical abnor-
malities in patients with T2DM. Dyslipidemia manage-
ment in people with diabetes mellitus, just like in any
other individual, starts with a flawless evaluation that
aims to identify secondary causes that might contribute
to the abnormal lipid profile [30].
The triglyceride-to-HDL cholesterol (TG/HDL) ratio
has been investigated recently for various potential clin-
ical uses in adult and paediatric populations [31,32]. Pre-
vious research has demonstrated its positive associations
with adverse cardio-metabolic risk factor profiles, meta-
bolic syndrome and prediction of incident diabetes or its
complications [31,32]. This may occur as the TG/HDL
ratio demonstrates an association with insulin resistance
[31-33]. A number of studies have shown that the TG/
HDL ratio has a good correlation with the generally
accepted methods to define insulin resistance and it istic patients
Male
Normal range Study group Mean
<200 143-292 219.1 ± 34.72
2 <150 90-432 250.0 ± 100.72
45-65 20-42 30.2 ± 7.4
<100 83-161 125.7 ± 21.42
ipids.
Table 4 Distribution of hepatosteatosis grades among
diabetics
Hepatosteatosis No. of patients %
Grade I 21 15.9
Grade II 21 15.9
Grade III 63 47.7
Grade IV 27 20.5
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positive correlation of TG/HDL ratio with HbA1c found
in this study is in line with the studies in the literature
(p < 0.01) [31-34].
Although obesity and T2DM commonly co-exist [35],
mean BMI in our study was in the overweight range.
Subjects enrolled in the study were the patients who
have diagnose of their diabetes for averagely 3 years.
They were under control of a dietitian since the date of
diagnose. This might be the cause that patients in our
study were mostly overweight, but not obese.
Lifestyle changes, including increased physical activity
and dietary modifications, are the milestones of manage-
ment. There is need for increased efforts by family mem-
bers, community and healthcare professionals towards
preventive based approach in the management of dia-
betes. This can be achieved through increased emphasis
on lifestyle modification strategies such as exercise, in-
creased dietary restrictions and weight control strategies
especially for those with impaired fasting glucose. Moni-
toring of lipid profile by blood tests done in regular inter-
vals in primary healthcare also might play an important
role to detect and take care of lipid abnormalities both in
diabetics and non-diabetics. One of the strengths of this
study is that it was the first study in Istanbul, Turkey that
looked at association between serum lipid profile and
blood glucose among patients with T2DM in primary
healthcare. To the best of our knowledge, there has not
been any previous study both performing blood tests and
hepatic ultrasound on this group of subjects. DespiteTable 5 Correlation studies between the blood glucose and s
FBG TC TG







The values expressed as Pearson correlation co-efficients.
1Correlation is significant at the 0.05 level.
2Correlation is significant at the 0.01 level.
3Correlation is significant at the 0.001 level.several important findings in the present study, relatively
small sample size is considered as a limitation of it.
The highest priority for diabetic individuals who have
poor glycaemic control should be to achieve almost near
normal blood glucose levels, with the expectation that this
effort will also cause an improvement in dyslipidemia
[22,36,37]. Our study clearly shows that lipid profiles are
abnormal in diabetes mellitus. Realizing that most of the
diabetics have a high probability of developing cardiovas-
cular and cerebrovascular disease, it is essential that an in-
dividual who is diabetic should take care of dyslipidemia.
Our study definitely indicates the presence of hyperlipid-
emia which might be hazardous for diabetics.
Conclusion
The present study suggested that common lipid abnormal-
ities during diabetes induced dyslipidemia are hyper-
cholesterolemia, hypertriglyceridemia and elevated LDL
cholesterol. Results suggest a high prevalence of dyslipid-
emia, which might be playing a major role in the develop-
ment of cardiovascular diseases and cerebrovascular
accidents among diabetic patients. The optimal care for
diabetic patients should include routine monitoring of
blood glucose and serum lipid profile. Efforts to achieve
lifestyle changes, such as weight reduction, physical exer-
cise and smoking cessation should be encouraged and
initiated first and then followed by medication with lipid
lowering drugs prescribed in evidence-based necessary
conditions. The optimum treatment with proper anti-
diabetic drugs to obtain fair glycaemic control should go
concomitantly with lipid lowering drugs as well as with
taken dietary precautions. When those mentioned above
are done, we might properly speak about the benefits that
primary healthcare could ensure to diabetics by the advan-
tage of monitoring patients more closely.
Methods
The cross-sectional study sample included Turkish par-
ticipants diagnosed with T2DM. The study was doneerum lipid profile variables of diabetic patients
LDL HDL Hepatosteatosis HbA1c
0.3161 −0.2201 0.7932 0.7722
0.213 0.061 0.7733 0.8703
0.8703 0.217 0.2991 0.3731
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partments of Family Medicine clinic of the Bezmialem
Vakif University Hospital in the largest city of Turkey,
namely Istanbul, in the north-west region of the country
and participating 132 subjects with T2DM (more than 6
months duration) were randomly selected and recruited
in the study. The patients whose taking multi-vitamin
supplementation or having hepatic, renal or metabolic
bone disorders (including parathyroid related problems)
were excluded from the study for the reason that those
conditions might affect the carbohydrate and lipid me-
tabolism in diabetes [38,39]. Also those patients having
history of malabsorption syndromes such as celiac dis-
ease or active malignancy or with active infection were
excluded from the study. Written informed consent was
taken from each subject, fulfilling the mentioned criteria
at above, before study inclusion. Study subjects were
asked to complete a generalized questionnaire that
contains demographic information including past and
present medical history, and to return after fasting for
more than 8 hours for anthropometry and blood with-
drawal. At the screening visit, blood samples were exam-
ined for levels of glucose and lipid profile. Subjects who
had abnormal levels of these at bio-chemical laboratory
tests were excluded.
Subjects were requested to visit the family medicine
outpatient clinic following an overnight fasted state
(≥8 hours) for anthropometry and blood withdrawal by
the clinic nurse and physician on duty, respectively.
Anthropometry included height (rounded to the nearest
0.5 cm), weight (rounded to the nearest 0.1 kg), and
mean systolic and diastolic blood pressure (mmHg).
Body mass index (BMI) was calculated as weight in
kilograms divided by height in square meters. Fasting
blood samples were collected and transferred immediately
to a non-heparinized tube for centrifugation. Collected
serum was then transferred to pre-labeled plain tubes and
delivered to the bio-chemistry laboratory in Bezmialem
Vakif University Hospital.
Fasting glucose, cholesterol and triglyceride were mea-
sured using an chemical auto-analyzer (Toshiba, Japan).
Cholesterol esters will be hydrolyzed by cholesterol
esterase. Cholesterol will be oxidized into cholest-4-en-
3-on and hydrogen peroxide by bacterial cholesterol oxi-
dase. Hydrogen peroxide in the presence of phenol and
amino-4-antipyrine forms a complex of red color show-
ing absorption maximum between 500–550 nm. It is
based on the principle that triglycerides in the serum
sample are hydrolyzed enzymatically by the action of
lipase to glycerol and fatty acids. The glycerol formed is
converted to glycerol phosphate by glycerol kinase (GK).
Glycerol phosphate is then oxidized to dihydroxyacetone
phosphate by glycerol phosphate oxidase (GPO). The
librated hydrogen peroxide is detected by a chromogenicacceptor, chlorophenol-4-aminoantipyrine, in the pres-
ence of peroxidase (POD). The red quinone formed is
proportional to the amount of triglycerides (TG) present
in the sample and is measured at 546 nm. High density
lipoprotein (HDL) is measured by using phosphotung-
state precipitation method based on the principle that
chylomicrons, very low density lipoprotein (VLDL) and low
density lipoprotein (LDL) fractions in serum or plasma are
separated from HDL by precipitating with phosphotungstic
acid and magnesium chloride. After centrifugation the
cholesterol in the HDL fraction which remains in the
supernatant is assayed with enzymatic cholesterol method
using cholesterol esterase, cholesterol oxidase, peroxidase
and the chromogen 4-aminoantipyrine. The LDL choles-
terol test is a two reagent homogenous system. The assay is
comprised of two distinct phases. In phase one a unique
detergent solubilizes cholesterol from non-LDL-lipoprotein
particles. This cholesterol is consumed by cholesterol ester-
ase, cholesterol oxidase, peroxidase and 4-aminoantipyrine
to generate a colorless end product. In phase two a second
detergent in reagent 2 releases cholesterol from the LDL li-
poproteins. This cholesterol reacts with cholesterol esterase,
cholesterol oxidase and a chromogen system to yield a blue
color complex which can be measured bichromatically at
540/660 nm. The resulting increase in absorbance is dir-
ectly proportional to the LDL concentration in the sample.
The value of VLDL cholesterol was calculated as one-fifth
of the concentration of triglycerides.
It should be noted that the Quality Assurance (QA)
standards are maintained by TS EN ISO 15189, whereas
the QA department audits the laboratory at regular
intervals. Ethical approval was taken from the institu-
tional review board (IRB) prior to the commencement of
the study.
Ultrasound could be used contributively in detecting
hepatosteatosis and it is a non-invasive and easily applicable
method. However, liver biopsy remains the only accurate
way to diagnose hepatosteatosis. There are 4 sonographic
findings of diffuse fatty change in the liver characteris-
ing different grades: (1) a diffuse hyperechoic echotexture
(bright liver), (2) increased liver echotexture compared
with the kidneys, (3) vascular blurring, and (4) deep
attenuation [40]. A hepatic ultrasound was performed for
every diabetic in the study group in order to evaluate
whether hepatosteatosis is present or not and, if present,
to detect the grade of hepatosteatosis by a radiologist.
Data were analyzed using the Statistical Package for
the Social Sciences version 16.0 (SPSS, Chicago, IL,
USA). Normal continuous variables were presented as
mean ± standard deviation. Test of significance was cal-
culated by unpaired student’s t test between cases and
controls. Correlation studies (Pearson’s correlation) were
performed between the variables of blood glucose and
serum lipid profile. Significance was set at p < 0.05.
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